Mesoblast's NeoFuse Stem Cell Product Shows Positive Results in Phase 2 Lumbar Spinal Fusion Trial

Phase 2 trial results using Mesoblast's allogeneic, or "off-the-shelf", Mesenchymal Precursor Cells demonstrated rates of fusion success that were comparable to the gold standard bone autograft At 12 months, fusion was achieved in 85.7% and 62.5% of patients in the low and high MPC treatment groups compared to 75% of patients who received bone ... (more)

http://www.globenewswire.com/news-release/2013/01/11/515892/10017878/en/Mesoblast-s-NeoFuse-Stem-Cell-Product-Shows-Positive-Results-in-Phase-2-Lumbar-Spinal-Fusion-Trial.html